Trivium Point Advisory’s CME Group CME Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.13M | Buy |
5,100
+170
| +3% | +$47K | 0.1% | 180 |
|
|
2026
Q1 | $1.46M | Sell |
4,930
-355
| -7% | -$105K | 0.26% | 93 |
|
|
2025
Q4 | $1.44M | Buy |
5,285
+15
| +0.3% | +$4.08K | 0.15% | 146 |
|
|
2025
Q3 | $1.42M | Sell |
5,270
-7,050
| -57% | -$1.92M | 0.15% | 140 |
|
|
2025
Q2 | $3.4M | Sell |
12,320
-610
| -5% | -$166K | 0.37% | 73 |
|
|
2025
Q1 | $3.43M | Sell |
12,930
-2,360
| -15% | -$582K | 0.43% | 68 |
|
|
2024
Q4 | $3.55M | Buy |
15,290
+3,560
| +30% | +$819K | 0.45% | 65 |
|
|
2024
Q3 | $2.68M | Sell |
11,730
-1,739
| -13% | -$360K | 0.37% | 87 |
|
|
2024
Q2 | $2.65M | Buy |
13,469
+433
| +3% | +$89.5K | 0.39% | 81 |
|
|
2024
Q1 | $2.81M | Buy |
13,036
+510
| +4% | +$107K | 0.6% | 52 |
|
|
2023
Q4 | $2.64M | Sell |
12,526
-316
| -2% | -$67.4K | 0.64% | 51 |
|
|
2023
Q3 | $2.59M | Sell |
12,842
-316
| -2% | -$62.8K | 0.71% | 42 |
|
|
2023
Q2 | $2.44M | Sell |
13,158
-552
| -4% | -$102K | 0.66% | 44 |
|
|
2023
Q1 | $2.63M | Buy |
13,710
+650
| +5% | +$118K | 0.71% | 39 |
|
|
2022
Q4 | $2.29M | Buy |
13,060
+365
| +3% | +$63.4K | 0.67% | 47 |
|
|
2022
Q3 | $2.23M | Buy |
12,695
+55
| +0.4% | +$10.9K | 0.69% | 39 |
|
|
2022
Q2 | $2.64M | Buy |
12,640
+186
| +1% | +$39.4K | 0.79% | 39 |
|
|
2022
Q1 | $3.03M | Buy |
12,454
+440
| +4% | +$103K | 0.67% | 47 |
|
|
2021
Q4 | $2.75M | Buy |
12,014
+127
| +1% | +$27.9K | 0.58% | 63 |
|
|
2021
Q3 | $2.4M | Buy |
11,887
+345
| +3% | +$69.9K | 0.57% | 58 |
|
|
2021
Q2 | $2.46M | Buy |
11,542
+978
| +9% | +$206K | 0.61% | 55 |
|
|
2021
Q1 | $2.16M | Buy |
10,564
+442
| +4% | +$87.1K | 0.58% | 56 |
|
|
2020
Q4 | $2.01M | Buy |
10,122
+616
| +6% | +$105K | 0.58% | 51 |
|
|
2020
Q3 | $1.59M | Buy |
9,506
+1,120
| +13% | +$189K | 0.56% | 60 |
|
|
2020
Q2 | $1.39M | Buy |
8,386
+826
| +11% | +$148K | 0.55% | 65 |
|
|
2020
Q1 | $1.37M | Sell |
7,560
-1,078
| -12% | -$215K | 0.7% | 55 |
|
|
2019
Q4 | $1.73M | Sell |
8,638
-150
| -2% | -$30.8K | 0.67% | 55 |
|
|
2019
Q3 | $1.89M | Sell |
8,788
-442
| -5% | -$92.4K | 0.87% | 41 |
|
|
2019
Q2 | $1.79M | Buy |
9,230
+615
| +7% | +$113K | 0.8% | 43 |
|
|
2019
Q1 | $1.42M | Buy |
8,615
+135
| +2% | +$23.9K | 0.66% | 67 |
|
|
2018
Q4 | $1.59M | Buy |
+8,480
| New | +$1.57M | 0.97% | 38 |
|
Other funds holding CME
Trivium Point Advisory's CME Position: Q2 2026 in Review
Trivium Point Advisory increased its CME Group (CME) stake by 3.4% in Q2 2026, buying an estimated $47K and bringing the position to 5,100 shares worth $1.13M. The position accounts for 0.1% of the portfolio, ranked #180.
Trivium Point Advisory first reported a position in CME in Q4 2018 and has held it in 31 quarters since. The position peaked at $3.55M in Q4 2024. 1,698 funds tracked by Wall St. Rank hold CME as of Q2 2026.
- Trivium Point Advisory held 5,100 shares of CME Group worth $1.13M as of Q2 2026.
- Trivium Point Advisory bought 170 CME Group shares in Q2 2026, an estimated $47K.
- CME Group made up 0.1% of Trivium Point Advisory's portfolio in Q2 2026, its #180 holding.
- Trivium Point Advisory first reported a position in CME Group in Q4 2018 and has held it in 31 quarters since.
- Trivium Point Advisory's CME Group position peaked at $3.55M in Q4 2024.
- 1,698 funds tracked by Wall St. Rank held CME Group as of Q2 2026.
Based on Trivium Point Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.